Capietto Aude-Hélène, Jhunjhunwala Suchit, Delamarre Lélia
cancer Immunology Department, Genentech, South San Francisco, CA, USA.
Bioinformatic Department, Genentech, south San Francisco, CA, USA.
Mol Cell Oncol. 2020 Apr 3;7(3):1740071. doi: 10.1080/23723556.2020.1740071. eCollection 2020.
Cancer mutations can elicit protective immunity. Computational methods are critical for selecting these neoantigens for immunotherapy. While significant progress has been made in the field in predicting peptide presentation, our understanding of which mutated peptide is recognized as foreign by T cells remains limited. We used mouse vaccination studies to examine the features of immunogenic neoantigens and demonstrated that the mutation position is an important criterion for predicting neoantigens.
癌症突变可引发保护性免疫。计算方法对于选择这些新抗原进行免疫治疗至关重要。虽然在预测肽呈递领域已取得重大进展，但我们对哪些突变肽被T细胞识别为外来肽的理解仍然有限。我们利用小鼠疫苗接种研究来检查免疫原性新抗原的特征，并证明突变位置是预测新抗原的一个重要标准。
